Article
Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.
JACC. Heart failure - 1 Feb 2015
Ho Carolyn Y, Lakdawala Neal K, Cirino Allison L, Lipshultz Steven E, Sparks Elizabeth, Abbasi Siddique A, Kwong Raymond Y, Antman Elliott M, Semsarian Christopher, González Arantxa, López Begoña, Diez Javier, Orav E John, Colan Steven D, Seidman Christine E
Abstract excerpt
OBJECTIVES: The study sought to assess the safety, feasibility, and effect of diltiazem as disease-modifying therapy for at-risk hypertrophic cardiomyopathy (HCM) mutation carriers. BACKGROUND: HCM is caused by sarcomere mutations and characterized by left ventricular hypertrophy (LVH) with increased risk of heart failure and sudden death. HCM typically cannot be diagnosed early in life, although subtle...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.